TY - JOUR
T1 - Langzeitanalyse von Parametern der Lebensqualität sowie klinischen, radiografischen, echokardiografischen und labordiagnostischen Variablen bei Hunden mit myxomatöser Mitralklappenerkrankung, die mit Pimobendan oder Benazepril behandelt werden: Die QUEST-Studie
AU - Haggstrom, Jens
AU - Boswood, Adrian
AU - O'Grady, Michael
AU - Jons, Olaf
AU - Smith, Sarah
AU - Borgarelli, Michele
AU - Gavaghan, Brad
AU - Kresken, Jan-Gerd
AU - Patteson, Mark
AU - Ablad, Bjorn
AU - Bussadori, Claudio M.
AU - Glaus, Tony
AU - Kovacevic, Alan
AU - Rapp, Martin
AU - Santilli, Roberto A.
AU - Tidholm, Anna
AU - Eriksson, Anders
AU - Belanger, Marie Claude
AU - Deinert, Michael
AU - Little, Chris J. L.
AU - Kvart, Clarence
AU - French, Anne
AU - Ronn-Landbo, Mette
AU - Wess, Gerhard
AU - Eggertsdottir, Anna
AU - O'Sullivan, M. Lynne
AU - Schneider, Matthias
AU - Lombard, Christophe W.
AU - Dukes-McEwan, Joe
AU - Willis, Ruth
AU - Louvet, Alexandre
AU - DiFruscia, Rocky
PY - 2014
Y1 - 2014
N2 - Background: Myxomatous mitral valve disease (MMVD) is an important cause of morbidity and mortality in dogsObjectives: To compare, throughout the period of follow-up of dogs that had not yet reached the primary endpoint, the longitudinal effects of pimobendan versus benazepril hydrochloride treatment on quality-of-life (QoL) variables, concomitant congestive heart failure (CHF) treatment, and other outcome variables in dogs suffering from CHF secondary to MMVD.Animals: A total of 260 dogs in CHF because of MMVD.Methods A prospective single-blinded study with dogs randomized to receive pimobendan (0.4-0.6 mg/kg/day) or benazepril hydrochloride (0.25-1.0 mg/kg/day) Differences in outcome variables and time to intensification of CHF treatment were compared.Results: A total of 124 dogs were randomized to pimobendan and 128 to benazepril. No difference was found between groups in QoL variables during the trial. Time from inclusion to 1st intensification of CHF treatment was longer in the pimobendan group (pimobendan 98 days, IQR 30-276 days versus benazepril 59 days, IQR 11-121 days; P = .0005). Postinclusion, dogs in the pimobendan group had smaller heart size based on VHS score (P = .013) and left ventricular diastolic (P = .035) and systolic (P = 0044) dimensions, higher body temperature (P = .030), serum sodium (P = .0027), and total protein (P = .0003) concentrations, and packed cell volume (P = .030) Incidence of arrhythmias was similar in treatment groups.Conclusions and clinical importance: Pimobendan versus benazepril resulted in similar QoL during the study, but conferred increased time before intensification of CHF treatment Pimobendan treatment resulted in smaller heart size, higher body temperature, and less retention of free water.
AB - Background: Myxomatous mitral valve disease (MMVD) is an important cause of morbidity and mortality in dogsObjectives: To compare, throughout the period of follow-up of dogs that had not yet reached the primary endpoint, the longitudinal effects of pimobendan versus benazepril hydrochloride treatment on quality-of-life (QoL) variables, concomitant congestive heart failure (CHF) treatment, and other outcome variables in dogs suffering from CHF secondary to MMVD.Animals: A total of 260 dogs in CHF because of MMVD.Methods A prospective single-blinded study with dogs randomized to receive pimobendan (0.4-0.6 mg/kg/day) or benazepril hydrochloride (0.25-1.0 mg/kg/day) Differences in outcome variables and time to intensification of CHF treatment were compared.Results: A total of 124 dogs were randomized to pimobendan and 128 to benazepril. No difference was found between groups in QoL variables during the trial. Time from inclusion to 1st intensification of CHF treatment was longer in the pimobendan group (pimobendan 98 days, IQR 30-276 days versus benazepril 59 days, IQR 11-121 days; P = .0005). Postinclusion, dogs in the pimobendan group had smaller heart size based on VHS score (P = .013) and left ventricular diastolic (P = .035) and systolic (P = 0044) dimensions, higher body temperature (P = .030), serum sodium (P = .0027), and total protein (P = .0003) concentrations, and packed cell volume (P = .030) Incidence of arrhythmias was similar in treatment groups.Conclusions and clinical importance: Pimobendan versus benazepril resulted in similar QoL during the study, but conferred increased time before intensification of CHF treatment Pimobendan treatment resulted in smaller heart size, higher body temperature, and less retention of free water.
KW - canine
KW - mitral regurgitation
KW - mortality
KW - therapy
KW - canine
KW - mitral regurgitation
KW - mortality
KW - therapy
UR - https://res.slu.se/id/publ/66130
U2 - 10.2377/0023-2076-59-117
DO - 10.2377/0023-2076-59-117
M3 - Artikel i vetenskaplig tidskrift
SN - 0023-2076
VL - 59
SP - 117
EP - 134
JO - Kleintier-praxis
JF - Kleintier-praxis
IS - 3
ER -